沐舒坦治疗重型颅脑损伤后肺部感染的临床分析

Clinical Study of Mucosolvan in Treatment of Lung Infection after Severe Brain Injury

目的:探讨沐舒坦对重型颅脑损伤后肺部感染的治疗作用.方法:选择GCS3～8分重型颅脑损伤后肺部感染的患者90例,随机选45例(实验组)加用沐舒坦治疗,另45例(对照组)未予沐舒坦治疗。所有患者其他治疗措施均基本相同。结果:实验组有42例感染控制,感染控制时间平均(7.8±2.6)d:对照组有35例感染控制,感染控制时间平均(14.1±3.2)d。实验组肺部感染控制率显著高于对照组(P<0.05),而控制感染平均时间显著短于对照组(P<0.05)。结论:沐舒坦治疗重型颅脑损伤后肺部感染有较好的临床疗效,值得临床推广应用。

Objective: To study the therapeutic effect of Mucosolvan on lung infection after severe brain injury. Methods: All 90 patients with lung cancer after severe brain injury (Glasgow coma scale score of 8 or less on admission) were randomly divided into the experimental group(45 cases) and the control group(45 cases) .The experimental group were treated by Mucosolvan and the control group treated without Mucosolvan. Results: The results showed that 42 cases of lung infection were controlled in the experimental group while in the control group,35 cases were controlled respectively.There were significant difference in two groups (P < 0.05); The time of lung infection controlled in the experimental group were shorter than that in control group (P < 0.01) . Conclusions:The effect of patients with lung infection after severe brain injury can be improved by administration Mucosolvan and it deserves further clinical applications.